幽门螺杆菌治疗：现状与未来。
Helicobacter pylori therapy: Present and future.
作者信息
De Francesco Vincenzo, Ierardi Enzo, Hassan Cesare, Zullo Angelo
机构信息
Vincenzo De Francesco, Enzo Ierardi, Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Ospedali Riuniti, 71100 Foggia, Italy.
出版信息
World J Gastrointest Pharmacol Ther. 2012 Aug 6;3(4):68-73. doi: 10.4292/wjgpt.v3.i4.68.
Abstract
Helicobacter pylori (H. pylori) plays a crucial role in the pathogenesis of chronic active gastritis, peptic ulcer and gastric mucosa-associated lymphoid tissue-lymphoma, and is also involved in carcinogenesis of the stomach. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. Several factors may help in the eradication of therapy failure. We reviewed both bacterial and host factors involved in therapeutic management of the H. pylori infection. In addition, we evaluated data on the most successful therapy regimens - sequential and concomitant therapies - currently available for H. pylori eradication.
摘要
幽门螺杆菌（H. pylori）在慢性活动性胃炎、消化性溃疡和胃黏膜相关淋巴组织淋巴瘤的发病机制中起关键作用，还参与胃癌的发生。幽门螺杆菌治疗对医生来说仍然是一项挑战，因为目前没有一线治疗方法能够治愈所有接受治疗患者的感染。有几个因素可能有助于解决治疗失败的问题。我们综述了幽门螺杆菌感染治疗管理中涉及的细菌和宿主因素。此外，我们评估了目前可用于根除幽门螺杆菌的最成功治疗方案——序贯疗法和联合疗法——的数据。
相似文献
1
Helicobacter pylori therapy: Present and future.幽门螺杆菌治疗：现状与未来。
World J Gastrointest Pharmacol Ther. 2012 Aug 6;3(4):68-73. doi: 10.4292/wjgpt.v3.i4.68.
2
Eradication therapy of Helicobacter pylori directly induces apoptosis in inflammation-related immunocytes in the gastric mucosa--possible mechanism for cure of peptic ulcer disease and MALT lymphoma with a low-grade malignancy.幽门螺杆菌根除治疗直接诱导胃黏膜中炎症相关免疫细胞凋亡——这可能是消化性溃疡疾病和低度恶性黏膜相关淋巴组织淋巴瘤治愈的机制。
Hepatogastroenterology. 2003 May-Jun;50(51):607-9.
3
Strategy for treatment of Helicobacter pylori infection in adults. I. Updated indications for test and eradication therapy suggested in 2000.成人幽门螺杆菌感染的治疗策略。I. 2000年建议的检测与根除治疗的更新指征。
Curr Pharm Des. 2000 Oct;6(15):1503-14. doi: 10.2174/1381612003399112.
4
Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.幽门螺杆菌的毒力因子基因型影响根除治疗的治愈率。
Arch Immunol Ther Exp (Warsz). 2009 Jan-Feb;57(1):45-56. doi: 10.1007/s00005-009-0007-z. Epub 2009 Feb 14.
5
6
Helicobacter pylori. One bacterium and a broad spectrum of human disease! An overview.幽门螺杆菌。一种细菌与广泛的人类疾病！综述。
J Physiol Paris. 2000 Mar-Apr;94(2):139-52. doi: 10.1016/s0928-4257(00)00160-1.
7
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.幽门螺杆菌感染管理的当前概念——《马斯特里赫特2-2000共识报告》
Aliment Pharmacol Ther. 2002 Feb;16(2):167-80. doi: 10.1046/j.1365-2036.2002.01169.x.
8
Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance.抗生素耐药性不断增加的时代下针对[具体病症，原文缺失]的新型有效治疗方案
Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017.
9
Helicobacter pylori: a pathogenic threat to the gastric mucosal barrier.幽门螺杆菌：对胃黏膜屏障的致病威胁。
Afr J Med Med Sci. 2015 Dec;44(4):289-96.
10
Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection.幽门螺杆菌感染根除后消化性溃疡和胃炎患者血浆胃饥饿素和瘦素水平的变化
BMC Gastroenterol. 2016 Oct 4;16(1):119. doi: 10.1186/s12876-016-0532-2.
引用本文的文献
1
Biomimetic cell membrane-coated poly(lactic--glycolic acid) nanoparticles for biomedical applications.用于生物医学应用的仿生细胞膜包覆聚乳酸-乙醇酸纳米粒
Bioeng Transl Med. 2022 Nov 2;8(2):e10441. doi: 10.1002/btm2.10441. eCollection 2023 Mar.
2
Telephone-Based Reeducation of Drug Administration for Eradication: A Multicenter Randomized Controlled Study.基于电话的根除药物管理再教育：一项多中心随机对照研究。
Gastroenterol Res Pract. 2020 Jul 31;2020:8972473. doi: 10.1155/2020/8972473. eCollection 2020.
3
First-line therapies for eradication: a critical reappraisal of updated guidelines.根除治疗的一线疗法：对更新指南的批判性重新评估。
Ann Gastroenterol. 2017;30(4):373-379. doi: 10.20524/aog.2017.0166. Epub 2017 Jun 1.
4
Treatment of Helicobacter pylori infection: Current and future insights.幽门螺杆菌感染的治疗：当前见解与未来展望
World J Clin Cases. 2016 Jan 16;4(1):5-19. doi: 10.12998/wjcc.v4.i1.5.
5
Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China.服药前每日电话再教育对幽门螺杆菌根除的影响：一项来自中国的前瞻性单中心研究。
World J Gastroenterol. 2015 Oct 21;21(39):11179-84. doi: 10.3748/wjg.v21.i39.11179.
6
High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study.高剂量埃索美拉唑和阿莫西林双重疗法用于一线根除幽门螺杆菌：一项概念验证研究。
Ann Gastroenterol. 2015 Oct-Dec;28(4):448-51.
7
Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study.北京消化不良症状患者分离出的幽门螺杆菌菌株的原发性抗生素耐药性：一项前瞻性系列研究。
World J Gastroenterol. 2015 Mar 7;21(9):2786-92. doi: 10.3748/wjg.v21.i9.2786.
8
9
Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: scenario from Saudi Arabia.幽门螺杆菌的流行病学及抗生素耐药模式：沙特阿拉伯的情况
Saudi J Gastroenterol. 2014 Jul-Aug;20(4):212-8. doi: 10.4103/1319-3767.136935.
10
Gastric MALT lymphoma: old and new insights.胃黏膜相关淋巴组织淋巴瘤：新见解与旧认识
Ann Gastroenterol. 2014;27(1):27-33.
本文引用的文献
1
Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy.5 天四联“伴随”疗法与 7 天标准三联疗法根除幽门螺杆菌的疗效比较研究。
J Clin Gastroenterol. 2013 Jan;47(1):21-4. doi: 10.1097/MCG.0b013e3182548ad4.
2
Helicobacter pylori and nonmalignant diseases.幽门螺杆菌与非恶性疾病。
Helicobacter. 2011 Sep;16 Suppl 1:33-7. doi: 10.1111/j.1523-5378.2011.00878.x.
3
Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal.幽门螺杆菌抗生素耐药机制：最新评估
World J Gastrointest Pathophysiol. 2011 Jun 15;2(3):35-41. doi: 10.4291/wjgp.v2.i3.35.
4
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.14 天三联、5 天伴随和 10 天序贯疗法治疗七个拉丁美洲地区幽门螺杆菌感染：一项随机试验。
Lancet. 2011 Aug 6;378(9790):507-14. doi: 10.1016/S0140-6736(11)60825-8. Epub 2011 Jul 21.
5
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.综述文章：非铋四联（联合）疗法根除幽门螺杆菌。
Aliment Pharmacol Ther. 2011 Sep;34(6):604-17. doi: 10.1111/j.1365-2036.2011.04770.x. Epub 2011 Jul 11.
6
Should quinolones come first in Helicobacter pylori therapy?喹诺酮类药物是否应作为幽门螺杆菌治疗的首选？
Therap Adv Gastroenterol. 2011 Mar;4(2):103-14. doi: 10.1177/1756283X10384171.
7
Efficacy, tolerability, and factors affecting the efficacy of the sequential therapy in curing Helicobacter pylori infection in clinical setting.在临床环境中，序贯疗法治疗幽门螺杆菌感染的疗效、耐受性和影响疗效的因素。
J Investig Med. 2011 Aug;59(6):917-20. doi: 10.2310/JIM.0b013e318217605f.
8
Vaccinating against Helicobacter pylori infection.接种疫苗以预防幽门螺杆菌感染。
Nat Rev Gastroenterol Hepatol. 2011 Mar;8(3):133-40. doi: 10.1038/nrgastro.2011.1. Epub 2011 Feb 8.
9
Sequential therapy for Helicobacter pylori eradication: is levofloxacin better?幽门螺杆菌根除的序贯疗法：左氧氟沙星效果更佳？
Gut. 2011 Nov;60(11):1604; author reply 1605-6. doi: 10.1136/gut.2010.231233. Epub 2010 Dec 29.
10
Worldwide H. pylori antibiotic resistance: a systematic review.全球范围内幽门螺杆菌抗生素耐药性：系统评价。
J Gastrointestin Liver Dis. 2010 Dec;19(4):409-14.
Zotero 插件